Organogenesis Holdings Inc. reported net product revenue of $100.8 million for the second quarter of 2025, a 23% decrease compared to $130.2 million in Q2 2024. This decline was primarily driven by a 25% decrease in Advanced Wound Care product revenue, partially offset by a 16% increase in Surgical & Sports Medicine revenue.
The company posted a net loss of $9.4 million, or $(0.10) per share, for the quarter, which was a decrease in net loss compared to $17.0 million in the prior year. Adjusted EBITDA, however, shifted to a loss of $(3.6) million, compared to an income of $15.6 million in Q2 2024.
Despite the challenging first half, Organogenesis reaffirmed its full-year 2025 net revenue guidance of $480 million to $510 million, and its profitability guidance. The company anticipates a significant improvement in business trends in the latter half of the year, driven by recently launched in-licensed products and a more stable market environment, with top-line data from the second Phase 3 ReNu study expected in September 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.